Shalender Bhasin, A Michael Lincoff, Steven E Nissen, Kathleen Wannemuehler, Marie E McDonnell, Anne L Peters, Nader Khan, Michael C Snabes, Xue Li, Geng Li, Kevin Buhr, Karol M Pencina, Thomas G Travison
IMPORTANCE: The effect of testosterone replacement therapy (TRT) in men with hypogonadism on the risk of progression from prediabetes to diabetes or of inducing glycemic remission in those with diabetes is unknown. OBJECTIVE: To evaluate the efficacy of TRT in preventing progression from prediabetes to diabetes in men with hypogonadism who had prediabetes and in inducing glycemic remission in those with diabetes. DESIGN, SETTING, AND PARTICIPANTS: This nested substudy, an intention-to-treat analysis, within a placebo-controlled randomized clinical trial (Testosterone Replacement Therapy for Assessment of Long-Term Vascular Events and Efficacy Response in Hypogonadal Men [TRAVERSE]) was conducted at 316 trial sites in the US...
February 5, 2024: JAMA Internal Medicine